Compare Ecolab Inc. (ECL) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecolab Inc. vs Inovio Pharmaceuticals Inc — how do they compare? Ecolab Inc. trades at $273.58 (market cap $76.06B), while Inovio Pharmaceuticals Inc trades at $1.13 (market cap $96.26M). The key difference: Ecolab Inc. is far larger — about 790.2× Inovio Pharmaceuticals Inc's market cap, and Ecolab Inc. pays a 1.08% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| ECL | INO | |
|---|---|---|
Market Cap | $76.06B | $96.26M |
Sector | Consumer Cyclical | Health |
52-Week High | $308.35 | $2.87 |
52-Week Low | $245.73 | $1.05 |
Enterprise Value | $84.81B | $67.27M |
Dividend Yield | 1.08% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ECL trades at $273.62, up 1.43% with a bearish technical signal despite strong analyst support. The company shows solid fundamentals with $16.08B revenue, 12.8% net margin, and 22.31% ROE. Recent Q1 2026 earnings met expectations while Q2 2026 results are pending. The $4.75B CoolIT acquisition strengthens AI cooling capabilities, positioning for long-term growth in high-tech markets.
ECL presents a compelling growth story with improving profitability and strategic acquisitions, though current valuation multiples appear elevated. Key risks include execution of recent acquisitions and rising cost pressures. With 76% analyst buy ratings and a $327.43 consensus target suggesting 20% upside, the stock offers potential for patient investors despite near-term technical weakness.
INO trades at $1.14, down 1.72% today, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 in 2025 but has consistently beaten EPS estimates recently. Cash flow remains negative, though operating expenses are declining. A key FDA decision on INO-3107 is expected by October 30, 2026, representing a major catalyst.
The outlook hinges on regulatory approval for INO-3107. While analyst consensus is moderately bullish (53% buy ratings), significant financial losses and high valuation ratios pose substantial risks. The stock is a high-risk, event-driven investment dependent on successful drug commercialization to reverse its negative profitability trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ecolab Inc.
Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.
Read more on ECL →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
